Genmab A/S (NASDAQ:GMAB) To See Near-Term Downside Pressure Despite Active Buyback
![]() |
Genmab enters the coming weeks with defensive technicals and mixed operating fundamentals while corporate actions supply episodic support. The current valuation as determined by WMDST classifies the stock as under-valued. |





